General
Preferred name
PAMIDRONIC ACID
Synonyms
Pamidronate (Disodium) ()
CGP 23339A ()
PAMIDRONATE DISODIUM ()
CGP 23339AE ()
Pamidronate disodium salt ()
Pamidronate ()
Pamidronate (disodium pentahydrate) ()
Disodium pamidronate ()
Pamidronate disodium hydrate ()
CGP-23339AE ()
Aredia ()
Pamidronate disodium pentahydrate ()
Ribodroat ()
Pamidronate (sodium salt) ()
P&D ID
PD010127
CAS
57248-88-1
40391-99-9
109552-15-0
1159812-33-5
Tags
natural product
drug
available
Approved by
FDA
First approval
1991
Drug Status
approved
Drug indication
Bone Resorption Inhibitor
Hypercalcaemia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pamidronic acid is a bisphosphonate drug. (GtoPdb)
DESCRIPTION Pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis. (BOC Sciences Bioactive Compounds)
DESCRIPTION Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate is a nitrogen-containingbisphosphonate, used to prevent osteoporosis. (BOC Sciences Bioactive Compounds)
Cell lines
4
Organisms
3
Compound Sets
30
AdooQ Bioactive Compound Library
A10694
A11685
BOC Sciences Bioactive Compounds
pamidronate-disodium-pentahydrate-cas-109552-15-0-item-84-54249
pamidronate-disodium-cas-57248-88-1-item-84-71945
Cayman Chemical Bioactives
23699
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL3989401
CHEMBL834
ChEMBL Drugs
CHEMBL3989401
CHEMBL834
Concise Guide to Pharmacology 2017/18
7259
Concise Guide to Pharmacology 2019/20
7259
Concise Guide to Pharmacology 2021/22
7259
Concise Guide to Pharmacology 2023/24
7259
Drug Repurposing Hub
DrugBank
DB00282
DrugBank Approved Drugs
DB00282
DrugCentral
2048
DrugCentral Approved Drugs
2048
DrugMAP
DMB4AVP
DrugMAP Approved Drugs
DMB4AVP
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
7259
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL834
Mcule NIBR MoA Box Subset
MCULE-4373491291
MedChem Express Bioactive Compound Library
HY-B0730
HY-B0012
NCATS Inxight Approved Drugs
OYY3447OMC
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
Pamidronate-Disodium
TargetMol Bioactive Compound Library
T1337
T8400
External IDs
79
Properties
(calculated by RDKit )
Molecular Weight
235.0
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
6
Rotatable Bonds
4
Ring Count
0
Aromatic Ring Count
0
cLogP
-1.66
TPSA
161.31
Fraction CSP3
1.0
Chiral centers
0.0
Largest ring
0.0
QED
0.32
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
¦Â-catenin
Farnesyl diphosphate synthase
HAP
FPPS
??-catenin
Wnt
??catenin
FDPS
Bacterial
β-catenin
MOA
osteoclastic proton pump inhibitor
protein-tyrosine phosphatase inhibitor
HBV
Farnesyl Pyrophosphate Synthase Inhibitors
bone resorption inhibitor
Pathway
Microbiology&virology
Cytoskeletal Signaling
Stem Cells
Anti-infection
Stem Cell/Wnt
Member status
member
Indication
hypercalcemia, Paget's disease, breast cancer, multiple myeloma
Disease Area
endocrinology, oncology, hematologic malignancy
Therapeutic Class
Antiinflammatory Agents
Source data